2009 financials
Generic Keppra hits UCB sales
March 3, 2010Sales and Marketing 2009 financials, Keppra, UCB
UCB’s sales fell 13% in 2009 as the pharma company faced the first full year of generic competition in the …
Zeltia continue strong growth
February 26, 2010Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia
Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …
Bayer pharma sales overcome European decline
February 26, 2010Sales and Marketing 2009 financials, Bayer, Xarelto
Bayer’s group sales dropped 5% to 31 billion euros in a “difficult year” for the company that saw a drop …
Merck KGaA posts modest revenue increase
February 24, 20102009 financials, Erbitux, Merck KGaA, Merck Serono, Rebif
German pharma company Merck has posted a modest rise in revenue amidst strong pharma growth. Revenues increased 2.1% to 7.7 …
Low Adderall sales hit Shire
February 22, 2010Sales and Marketing 2009 financials, Adderall, Shire
Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR. Product sales were down …
Cephalon posts strong figures
February 12, 2010Sales and Marketing 2009 financials, Cephalon
US–based specialty pharma company Cephalon, best known for its sleep disorder treatment Provigil, has posted an 11% increase in sales …
Strong showing for Sanofi-Aventis in 2009
February 11, 20102009 financials, Sanofi-Aventis
Sanofi-Aventis made large gains in emerging markets, vaccines and consumer healthcare last year, helping produce 8.5 billion euros in net …
GSK confirms job cuts but avoids specifics
February 5, 2010Research and Development, Sales and Marketing 2009 financials, GlaxoSmithKline
GlaxoSmithKline has sidestepped questions about the internal fall-out from its new plan to slash R&D infrastructure costs. Presenting the company’s …
Zeftera problems weigh down Basilea
February 5, 2010Sales and Marketing 2009 financials, Basilea, Zeftera
Specialist Swiss pharma company Basilea has announced a doubling of its revenues in 2009, thanks to the launch of its …
Wyeth acquisition yet to shake Pfizer’s Lipitor dependence
February 4, 2010Sales and Marketing 2009 financials, Lipitor, Pfizer
Pfizer’s profits rose by 7% last year on the back of a 4% increase in revenue driven by cholesterol treatment …
Genentech integration hits Roche profits
February 3, 2010Sales and Marketing 2009 financials, Genentech, Roche
Roche achieved healthy sales growth in 2009 but saw a 22% drop in net income due to the cost gaining …
Novo buoyed by insulin portfolio
February 2, 2010Sales and Marketing 2009 financials, Novo Nordisk, Victoza
Danish pharma company Novo Nordisk managed a double-digit rise in sales and profits in 2009, buoyed by insulin products NovoRapid, …
Healthy growth for Lilly but Effient doubts raised
February 1, 2010Sales and Marketing 2009 financials, lilly
Lilly’s revenues for the full year rose 7% in 2009, thanks to a growth in sales of Zyprexa, the flagship …
BMS profits buoyant after Mead Johnson jettisoned
February 1, 2010Sales and Marketing 2009 financials, BMS, Mead Johnson
Bristol-Myers Squibb’s have revealed continued strong sales of the anti-blood clotting treatment Plavix and the antipsychotic Abilify and a huge …
Latest content
Five Facts about cardiovascular disease
